CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · IEX Real-Time Price · USD
1.380
0.00 (0.00%)
Jul 22, 2024, 10:04 AM EDT - Market open
CytomX Therapeutics Employees
As of December 31, 2023, CytomX Therapeutics had 122 total employees, including 120 full-time and 2 part-time employees. The number of employees increased by 4 or 3.39% compared to the previous year.
Employees
122
Change (1Y)
4
Growth (1Y)
3.39%
Revenue / Employee
$976,869
Profits / Employee
$135,516
Market Cap
108.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
FibroGen | 486 |
InterCure | 270 |
BrainsWay | 134 |
IO Biotech | 68 |
Elutia | 54 |
Journey Medical | 41 |
Regulus Therapeutics | 30 |
Zentek | 24 |
CTMX News
- 4 weeks ago - CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - GlobeNewsWire
- 2 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - CytomX stock down 30% despite encouraging cancer study results - Invezz
- 2 months ago - CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) - GlobeNewsWire